Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) up 16.2% since last earnings report: Can it continue?
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...
14don MSN
Recursion Pharmaceuticals just hit a 52-week low. Is this former Nvidia holding a smart buy now?
The stock looks cheap, but appearances can be deceiving.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results